Rifampin-divalproex drug-drug interaction in an adult patient: A case report
The divalproex (DVP) package insert states that rifampin may increase the oral clearance of valproate by 40% and that valproic acid derivative dose adjustments may be required when starting or stopping rifampin. However, the overall clinical significance of this drug-drug interaction remains unclear...
Saved in:
Main Authors: | Christine Doran, PharmD (Author), Michael Moro, MEd (Author), Jennifer Green, DO (Author), Kristen N. Gardner, PharmD, BCPP (Author) |
---|---|
Format: | Book |
Published: |
American Association of Psychiatric Pharmacists,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differences in serum concentration with valproate oral solution versus delayed-release divalproex in an adherent patient
by: Davis Erica A. K. PharmD, BCPS, BCPP
Published: (2023) -
Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient
by: Reynolds Jamie PharmD, et al.
Published: (2023) -
Best practices for documentation of psychotropic drug-drug interactions in an adult psychiatric clinic
by: Kathryn Collins, PharmD, MSPH, et al.
Published: (2023) -
Evaluation of drug-drug interactions in hospitalized patients on medications for OUD
by: Olivia Berger, PharmD, et al.
Published: (2021) -
Managing acute agitation and aggression in the world of drug shortages
by: Jennifer Miller, PharmD, BCPP
Published: (2021)